|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ARGLU1 |
Gene summary for ARGLU1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ARGLU1 | Gene ID | 55082 |
| Gene name | arginine and glutamate rich 1 | |
| Gene Alias | ARGLU1 | |
| Cytomap | 13q33.3 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A0A024RDW4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55082 | ARGLU1 | GSM4909281 | Human | Breast | IDC | 2.95e-02 | 1.89e-01 | 0.21 |
| 55082 | ARGLU1 | GSM4909282 | Human | Breast | IDC | 1.60e-41 | 7.55e-01 | -0.0288 |
| 55082 | ARGLU1 | GSM4909287 | Human | Breast | IDC | 1.14e-08 | 3.29e-01 | 0.2057 |
| 55082 | ARGLU1 | GSM4909294 | Human | Breast | IDC | 6.95e-10 | -3.97e-01 | 0.2022 |
| 55082 | ARGLU1 | GSM4909296 | Human | Breast | IDC | 2.04e-13 | -3.57e-01 | 0.1524 |
| 55082 | ARGLU1 | GSM4909297 | Human | Breast | IDC | 1.13e-14 | -2.29e-01 | 0.1517 |
| 55082 | ARGLU1 | GSM4909298 | Human | Breast | IDC | 6.02e-04 | 2.37e-01 | 0.1551 |
| 55082 | ARGLU1 | GSM4909301 | Human | Breast | IDC | 4.86e-03 | 2.16e-01 | 0.1577 |
| 55082 | ARGLU1 | GSM4909311 | Human | Breast | IDC | 4.96e-32 | -5.01e-01 | 0.1534 |
| 55082 | ARGLU1 | GSM4909312 | Human | Breast | IDC | 7.85e-11 | -3.53e-01 | 0.1552 |
| 55082 | ARGLU1 | GSM4909313 | Human | Breast | IDC | 4.86e-02 | -1.49e-02 | 0.0391 |
| 55082 | ARGLU1 | GSM4909315 | Human | Breast | IDC | 6.06e-07 | -4.35e-01 | 0.21 |
| 55082 | ARGLU1 | GSM4909316 | Human | Breast | IDC | 1.48e-03 | -5.43e-01 | 0.21 |
| 55082 | ARGLU1 | GSM4909317 | Human | Breast | IDC | 3.79e-06 | 3.09e-01 | 0.1355 |
| 55082 | ARGLU1 | GSM4909319 | Human | Breast | IDC | 2.39e-36 | -3.95e-01 | 0.1563 |
| 55082 | ARGLU1 | GSM4909320 | Human | Breast | IDC | 1.10e-03 | -2.30e-01 | 0.1575 |
| 55082 | ARGLU1 | GSM4909321 | Human | Breast | IDC | 1.12e-13 | -1.64e-01 | 0.1559 |
| 55082 | ARGLU1 | brca2 | Human | Breast | Precancer | 3.89e-03 | -1.23e-02 | -0.024 |
| 55082 | ARGLU1 | NCCBC14 | Human | Breast | DCIS | 1.19e-16 | -3.66e-01 | 0.2021 |
| 55082 | ARGLU1 | NCCBC2 | Human | Breast | DCIS | 9.16e-03 | -6.39e-02 | 0.1554 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ARGLU1 | SNV | Missense_Mutation | novel | c.736N>A | p.Arg246Ser | p.R246S | Q9NWB6 | protein_coding | deleterious(0) | benign(0.106) | TCGA-AC-A3BB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
| ARGLU1 | SNV | Missense_Mutation | novel | c.476N>A | p.Arg159Gln | p.R159Q | Q9NWB6 | protein_coding | deleterious(0.01) | possibly_damaging(0.644) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ARGLU1 | SNV | Missense_Mutation | c.289N>A | p.Glu97Lys | p.E97K | Q9NWB6 | protein_coding | deleterious(0.02) | benign(0.117) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ARGLU1 | SNV | Missense_Mutation | novel | c.35N>T | p.Ser12Phe | p.S12F | Q9NWB6 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.983) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ARGLU1 | SNV | Missense_Mutation | c.661N>A | p.Glu221Lys | p.E221K | Q9NWB6 | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| ARGLU1 | SNV | Missense_Mutation | c.473T>A | p.Leu158His | p.L158H | Q9NWB6 | protein_coding | tolerated(0.06) | probably_damaging(0.993) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| ARGLU1 | SNV | Missense_Mutation | c.731G>A | p.Arg244Gln | p.R244Q | Q9NWB6 | protein_coding | tolerated(0.75) | probably_damaging(0.947) | TCGA-F4-6703-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| ARGLU1 | SNV | Missense_Mutation | c.692N>T | p.Arg231Ile | p.R231I | Q9NWB6 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ARGLU1 | SNV | Missense_Mutation | c.734A>C | p.Gln245Pro | p.Q245P | Q9NWB6 | protein_coding | deleterious(0.02) | probably_damaging(0.923) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| ARGLU1 | SNV | Missense_Mutation | novel | c.56N>C | p.Lys19Thr | p.K19T | Q9NWB6 | protein_coding | deleterious(0) | possibly_damaging(0.859) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |